Saturday
August
23
2014
2:30 am
Weather

  Home
  Local News
  State / National / World
  Sports
  Opinion / Letters
  Business
  Arts / Entertainment
  Lifestyle
  Obituaries
  Calendar
  Submit Event
  Comics / Games
  Classifieds
  DJ Designers
  Archives
  Advertise With Us
  About Us
 
 
 
 

Check out our archive of Dining Guides - Yum!

FDA approves clears new leukemia drug from Roche
November 02, 2013, 05:00 AM The Associated Press

WASHINGTON — The Food and Drug Administration on Friday approved a new drug from South San Francisco-based Roche to help treat patients with a type of cancer of the blood and bone marrow.

The agency cleared Gazyva to fight chronic lymphocytic leukemia in combination with chemotherapy in patients who haven’t previously been treated for the disease.

Gazyva works by killing cancer cells and encouraging the immune system to fight against them.

Chronic lymphocytic leukemia develops slowly over time and is usually diagnosed in the elderly. More than 15,600 Americans will be diagnosed and 4,580 of them will die from the disease this year, according to estimates from the National Cancer Institute.

The FDA approved the drug based on a study showing Gazyva plus chemotherapy was superior to chemotherapy alone at slowing the progress of the disease. Patients treated with Gazyva had median survival of 23 months before death, relapse or worsening of their disease. That compares with 11.1 months for the chemotherapy patients.

The injectable biotech drug is the first medicine approved under FDA’s breakthrough designation, which was authorized by Congress last year. The new designation is designed to speed up the approval of promising drugs by providing companies with extra meetings and earlier communication with FDA scientists to discuss drug development.

Gazyva will be marketed by Roche’s Genentech unit, which is based in South San Francisco.

A spokeswoman for Genentech said the drug would cost $41,300 for one course of treatment, which lasts six months.

Common side effects seen in company studies included anemia, fever, muscle and bone pain and lower levels of white blood cells.

 

 

Tags: gazyva, patients, chemotherapy, disease, cancer, approved,


Other stories from today:

 

 
Print this Page Print this Page  |  Bookmark and Share
<< Back
 
Return To Archives
 
  


 
 
 
Daily Journal Quick Poll
 
Where is the violence most concerning to you?

Iraq
Ukraine
Syria
Ferguson
Israel

 

 
 
 
 
 
 
 
  
 
  
 
©2014 San Mateo Daily Journal
San Mateo County courts